The Rise and Fall of 23andMe From $6 Billion Valuation to Penny Stock | Anne Wojcicki

23andMe is fighting for its survival, 23andme has since suffered a staggering 98% drop in valuation from its peak of $6 billion. The company is now plagued by privacy concerns and battles with hackers who managed to steal genetic data from its platform, and it’s Facing challenges with its business model and ongoing worries about data privacy, the company has seen its valuation dropping to nearly zero, putting it at risk of being delisted by Nasdaq. The company reduced its staff by a quarter last year through three rounds of layoffs and a subsidiary sale, and 23andME has never made a profit and is burning cash so quickly it could run out by 2025. 23andME is currently going through tough times as it struggles to survive in this challenging environment. But what happened? watch the video